Photo of Anthony V. D'Amico,  MD, PhD

Anthony V. D'Amico, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-7936
Fax: (617) 975-0912


adamico@partners.org

Anthony V. D'Amico, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Radiation Oncology, Harvard Medical School
  • Chief, Genitourinary Radiation Oncology, Brigham And Women's Hospital
  • Chief, Genitourinary Radiation Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research is focused on two levels. At the basic science level, I have independent funding to support work in two laboratories. One lab is investigating the effect that benign prostatic epithelial and stromal cells have on the growth of juxtaposed malignant prostatic epithelial cells. This work aims to explain an improved PSA failure survival that I noted in prostate cancer patients managed with RT or surgery who also had moderate benign prostatic hypertrophy. The second lab is dedicated to the synthesis of prostate specific antigen cleavable pro-drugs whose target is the androgen independent metastatic prostate cancer cell.

On the clinical research level, I am the principal investigator of a national phase II prospective trial which will determine ability of endorectal coil MRI to assess androgen responsiveness and outcome (cause-specific and overall survival) after external beam radiation therapy and androgen suppression therapy for prostate cancer. I am also the principal investigator of a phase III prospective randomized trial evaluating the impact on survival (cause-specific and overall) from the addition of androgen suppression therapy to external beam radiation therapy for localized prostate cancer. I have developed a staging system for clinically localized prostate cancer from retrospective data analysis of radiation and surgically managed patients and with others I am prospectively attempting to validate it. Other retrospective studies that I am leading include identification of the optimal patients for interstitial prostate brachytherapy, external beam plus interstitial prostate brachytherapy, and androgen suppression plus external beam and interstitial prostate brachytherapy. These studies will be the basis for patient selection for prospective trials assessing the relative efficacy of these treatments on cause-specific and overall survival.

I have developed a new way of delivering interstitial radiation therapy for select patients with prostate cancer. Using the magnetic resonance image guided system at the Brigham and Women's Hospital, dose distributions that optimize dose to the prostate while minimizing dose to normal surrounding and indwelling structures have been achieved through the use of real time imaging and dosimetry. Ongoing research projects include (i) outcomes testing (cancer control - PSA, cause specific and overall survival and quality of life [GI, GU, sexual] - using a prospectively validated instrument), (ii) dose escalation studies in the intra-prostatic endorectal coil MR signal abnormality consistent with tumor, and a prospective randomized trial comparing the results of MR and ultrasound guided brachytherapy for select patients with prostate cancer. Other planned applications of this MR image guided device include interstitial implantation for locally advanced cancers of the female gynecological tract.

Currently I have created an interdisciplinary team whose goals are first, to define the molecular markers that characterize the key steps involved in the pathogenesis of prostate cancer so that these events can become targets for experimental therapeutics. The second goal is to develop a molecular imaging methodology by combining endorectal coil MRI and optical imaging in conjunction with uniquely designed photosensitive contrast agents that are the substrates for the specific gene products of interest.

Publications

Powered by Harvard Catalyst
  • D'Amico AV. Personalizing the duration of androgen-deprivation therapy use in the management of intermediate-risk prostate cancer. J Clin Oncol 2015; 33:301-3. PubMed
  • Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL. Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer? Am J Med 2015. PubMed
  • Nguyen PL, D'Amico AV. Toward Personalizing the Use of Androgen Deprivation Therapy to Maximize Benefit and Minimize Harm. Eur Urol 2014. PubMed
  • Keane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico AV. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer 2014. PubMed
  • Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL. Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. Brachytherapy 2014. PubMed
  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. 2014. PubMed
  • Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL. Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer. Clin Genitourin Cancer 2014. PubMed
  • D'Amico AV. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis. J Clin Oncol 2014; 32:1183-5. PubMed
  • Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV. Maximum Tumor Diameter and the Risk of Prostate-Specific Antigen Recurrence After Radical Prostatectomy. Clin Genitourin Cancer 2014. PubMed
  • Tseng YD, Paciorek AT, Martin NE, D'Amico AV, Cooperberg MR, Nguyen PL. Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer 2014; 120:824-32. PubMed
  • Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The Effect of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer. Clin Genitourin Cancer 2014. PubMed
  • Cheney MD, Chen MH, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV. Greatest Percentage of Involved Core Length and the Risk of Death From Prostate Cancer in Men With Highest Gleason Score ≥ 7. Clin Genitourin Cancer 2014. PubMed
  • D'Amico AV. US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun. J Clin Oncol 2014; 32:362-4. PubMed
  • Chandra RA, Chen MH, Zhang D, Loffredo M, D'Amico AV. Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial. Prostate Cancer 2014; 2014:478983. PubMed
  • Mirabeau-Beale K, Chen MH, D'Amico AV. Prior-cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate-cancer-specific and all-cause mortality. ISRN Oncol 2014; 2014:736163. PubMed
  • Braunstein LZ, Chen MH, Loffredo M, Kantoff PW, D'Amico AV. Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer 2014; 2014:230812. PubMed
  • Martin NE, Chen MH, Beard CJ, Nguyen PL, Loffredo MJ, Renshaw AA, Kantoff PW, D'Amico AV. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer 2014; 2014:912943. PubMed
  • Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. Prostate Cancer 2014; 2014:395078. PubMed
  • Punnen S, Cooperberg MR, D'Amico AV, Karakiewicz PI, Moul JW, Scher HI, Schlomm T, Freedland SJ. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013; 64:905-15. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 2013; 11:1364-72. PubMed
  • Aizer AA, D'Amico AV. Should all colorectal cancer patients over age 60 be screened for prostate cancer? Oncology (Huntingt) 2013; 27:1032-8. PubMed
  • Talcott JA, Manola J, Chen RC, Clark JA, Kaplan I, D'Amico AV, Zietman AL. Using Patient-Reported Outcomes to Assess and Improve Prostate Cancer Brachytherapy. BJU Int 2013. PubMed
  • Kim MB, Chen MH, de Castro M, Loffredo M, Kantoff PW, D'Amico AV. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer 2013; 119:3280-6. PubMed
  • D'Amico AV. Adjuvant versus salvage post-prostatectomy radiation therapy: a critical review of the evidence. J Urol 2013; 190:450-1. PubMed
  • D'Amico AV. Prostate cancer: where we have been, where we are, and where we are going. Semin Radiat Oncol 2013; 23:155-6. PubMed
  • Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy 2013. PubMed
  • Nanda A, Chen MH, Moran BJ, Braccioforte MH, D'Amico AV. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2013; 85:e209-15. PubMed
  • D'Amico AV. Personalizing the Management of Men with Intermediate-risk Prostate Cancer. Eur Urol 2013. PubMed
  • Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int 2013. PubMed
  • Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: A decision analysis. Cancer 2013. PubMed
  • Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology 2012; 81:130-4. PubMed
  • Chen RC, Zhang Y, Chen MH, McMahon E, Loffredo M, McPherson CP, Nguyen AU, Nguyen PL, D'Amico AV. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. BJU Int 2012; 110:1690-5. PubMed
  • Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int 2012; 110:1252-6. PubMed
  • Zakeri K, Rose BS, Gulaya S, D'Amico AV, Mell LK. Competing event risk stratification may improve the design and efficiency of clinical trials: Secondary analysis of SWOG 8794. Contemp Clin Trials 2012; 34:74-79. PubMed
  • Hegde JV, Chen MH, Mulkern RV, Fennessy FM, D'Amico AV, Tempany CM. Preoperative 3-Tesla Multiparametric Endorectal Magnetic Resonance Imaging Findings and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men With Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2012. PubMed
  • Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol 2012; 30:3540-4. PubMed
  • Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol 2012; 188:1151-6. PubMed
  • Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, Katin M, Salenius S, D'Amico AV. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int 2012; 110:1116-21. PubMed
  • Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM). BJU Int 2012; 110:973-9. PubMed
  • Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Neoadjuvant Hormonal Therapy Use and the Risk of Death in Men with Prostate Cancer Treated with Brachytherapy Who Have No or at Least a Single Risk Factor for Coronary Artery Disease. Eur Urol 2012. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30:3071-6. PubMed
  • D'Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N Engl J Med 2012; 367:e11. PubMed
  • Catalona WJ, D'Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 2012; 157:137-8. PubMed
  • Hattangadi JA, Chen MH, D'Amico AV. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5窶ハg/mL and the risk of death. BJU Int 2012. PubMed
  • D'Amico AV. Prostate-cancer mortality after PSA screening. N Engl J Med 2012; 366:2229; author reply 2230-1. PubMed
  • D'Amico AV. Future of Treatment for Low-Risk Prostate Cancer: For All, for Some, or for None? J Clin Oncol 2011. PubMed
  • Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D'Amico AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 2011. PubMed
  • Hattangadi JA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. Brachytherapy 2011. PubMed
  • Nguyen PL, Chen MH, Goldhaber SZ, Martin NE, Beard CJ, Dosoretz DE, Katin MJ, Ross R, Salenius SA, D'Amico AV. Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation. Cancer 2011; 117:406-13. PubMed
  • Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials. J Urol 2010; 185:116-20. PubMed
  • D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int 2010; 106:1618-22. PubMed
  • Williams SB, Chen MH, D'Amico AV, Weinberg AC, Kacker R, Hirsch MS, Richie JP, Hu JC. Radical Retropubic Prostatectomy and Robotic-assisted Laparoscopic Prostatectomy: Likelihood of Positive Surgical Margin(s). Urology 2010; 76:1097-101. PubMed
  • D'Amico AV. Is long-term androgen suppression right for everyone with locally advanced prostate cancer? Lancet Oncol 2010; 11:1016-7. PubMed
  • Crawford ED, Grubb R, Black A, Andriole GL, Chen MH, Izmirlian G, Berg CD, D'Amico AV. Comorbidity and Mortality Results From a Randomized Prostate Cancer Screening Trial. J Clin Oncol 2010. PubMed
  • Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D'Amico AV, Nguyen PL. Which Patients With Undetectable PSA Levels 5 Years After Radical Prostatectomy Are Still at Risk of Recurrence?-Implications for a Risk-adapted Follow-up Strategy. Urology 2010; 76:1201-5. PubMed
  • Williams SB, D'Amico AV, Weinberg AC, Gu X, Lipsitz SR, Hu JC. Population-based determinants of radical prostatectomy surgical margin positivity. BJU Int 2010. PubMed
  • Choueiri TK, D'Amico AV, Chen MH. Reply to impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010. PubMed
  • Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010; 106:979-85. PubMed
  • Choi WW, Gu X, Lipsitz SR, D'Amico AV, Williams SB, Hu JC. The effect of minimally invasive and open radical prostatectomy surgeon volume. Urol Oncol 2010. PubMed
  • Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int 2010; 106:627-32. PubMed
  • Hu JC, Prasad SM, Gu X, Williams SB, Lipsitz SR, Nguyen PL, Choueiri TK, Choi WW, D'Amico AV. Determinants of Performing Radical Prostatectomy Pelvic Lymph Node Dissection and the Number of Lymph Nodes Removed in Elderly Men. Urology 2010. PubMed
  • D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Causes of Death in Men with Prevalent Diabetes and Newly Diagnosed High- Versus Favorable-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys 2010; 77:1329-37. PubMed
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV. Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group. Int J Radiat Oncol Biol Phys 2010; 77:1046-52. PubMed
  • Nanda A, D'Amico AV. Hormonal therapy and radiation for prostate cancer: is it safe? Expert Rev Anticancer Ther 2010; 10:979-81. PubMed
  • Nguyen PL, D'Amico AV. Deciding which patients to treat with salvage radiotherapy after prostatectomy. Oncology (Huntingt) 2010; 24:705, 711. PubMed
  • D'Amico AV, Goldhaber SZ. Ask the doctor. A year ago, I had an orchiectomy for prostate cancer; my PSA is now 0.74. Not long afterward, I had two cardiac stents implanted. I still have some angina and shortness of breath. I started Ranexa a couple of weeks ago, which helps my angi Harv Heart Lett 2010; 20:8. PubMed
  • Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men with Small Prostate Size. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 2010; 116:2590-5. PubMed
  • D'Amico AV. Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer. J Clin Oncol 2010; 28:2651-2. PubMed
  • Hoffman KE, Nguyen PL, Ng AK, D'Amico AV. Prostate Cancer Screening in Men 75 Years Old or Older: An Assessment of Self-Reported Health Status and Life Expectancy. J Urol 2010; 183:1798-802. PubMed
  • Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Predictors of Prostate Cancer-Specific Mortality in Elderly Men with Intermediate-Risk Prostate Cancer Treated with Brachytherapy with or without External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys 2010; 77:147-52. PubMed
  • Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int 2010; 105:1417-22. PubMed
  • Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010; 116:1887-92. PubMed
  • Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Total Androgen Blockade Versus a Luteinizing Hormone-Releasing Hormone Agonist Alone in Men with High-Risk Prostate Cancer Treated with Radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:1439-44. PubMed
  • Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT, . The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology 2010; 75:623-9. PubMed
  • Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, . Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the american heart association, american cancer society, and american urological association: endorsed by the american society for radiation oncology. Circulation 2010; 121:833-40. PubMed
  • Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer 2010; 116:837-42. PubMed
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer 2010; 116:610-5. PubMed
  • Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. J Natl Compr Canc Netw 2010; 8:162-200. PubMed
  • Cormack RA, Sridhar S, Suh WW, D'Amico AV, Makrigiorgos GM. Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices. Int J Radiat Oncol Biol Phys 2010; 76:615-23. PubMed
  • Nguyen PL,Chen MH,Renshaw AA,Loffredo M,Kantoff PW,D'Amico AV. Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations. Int J Radiat Oncol Biol Phys 2010; 76:337-41. PubMed
  • Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Evaluating the Combined Effect of Comorbidity and Prostate-Specific Antigen Kinetics on the Risk of Death in Men After Prostate-Specific Antigen Recurrence. J Clin Oncol 2009; 27:6000-5. PubMed
  • Hu JC, Gu X, Lipsitz SR, Barry MJ, D'Amico AV, Weinberg AC, Keating NL. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302:1557-64. PubMed
  • Chen RC,Sadetsky N,Chen MH,Carroll PR,D'Amico AV. Maximum vs. Mono Androgen Blockade and the Risk of Recurrence in Men with Localized Prostate Cancer Undergoing Brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75:36-9. PubMed
  • D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW. Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death. Int J Radiat Oncol Biol Phys 2009; 75:10-5. PubMed
  • Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302:866-73. PubMed
  • D'Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, Chen MH. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009; 27:3923-8. PubMed
  • Nanda A,Chen MH,Renshaw AA,D'Amico AV. Gleason Pattern 5 Prostate Cancer: Further Stratification of Patients With High-Risk Disease and Implications for Future Randomized Trials. Int J Radiat Oncol Biol Phys 2009; 74:1419-23. PubMed
  • D'Amico AV, Chen MH. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer. J Clin Oncol 2009; 27:3575-6. PubMed
  • Nguyen PL,Chen MH,Hoffman KE,Katz MS,D'Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 2009; 74:104-9. PubMed
  • Nanda A,Chen MH,D'Amico AV. Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. J Clin Oncol 2009; 27:1728-9; author reply 1729. PubMed
  • Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115:981-7. PubMed
  • Nguyen PL,Chen MH,Catalona WJ,Moul JW,Sun L,D'Amico AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2008; 73:659-64. PubMed
  • Chen AB,D'Amico AV,Neville BA,Steyerberg EW,Earle CC. Provider case volume and outcomes following prostate brachytherapy. J Urol 2008; 181:113-8; discussion 118. PubMed
  • D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008; 113:3290-7. PubMed
  • Nguyen PL,Chen MH,Catalona WJ,Alexander BM,Roehl KA,Loeb S,D'Amico AV. Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer 2008; 113:3146-52. PubMed
  • Nanda A,D'Amico AV. Combined radiation and hormonal therapy or dose escalation for men with unfavourable-risk prostate cancer: an evidence-based approach using a synthesis of randomized clinical trials. BJU Int 2008; 102:1366-8. PubMed
  • Loeb S,Sutherland DE,D'Amico AV,Roehl KA,Catalona WJ. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 2008; 72:1116-20; discussion 1120. PubMed
  • Sommers BD,Beard CJ,D'Amico AV,Kaplan I,Richie JP,Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113:2058-67. PubMed
  • Hoffman KE,Chen MH,Punglia RS,Beard CJ,D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 2008; 26:3937-42. PubMed
  • Martin NE,Chen MH,Catalona WJ,Loeb S,Roehl KA,D'Amico AV. The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis. Cancer 2008; 113:717-22. PubMed
  • D'Amico AV,Chen MH,Renshaw AA,Loffredo B,Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008; 26:2979-83. PubMed
  • Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 2008; 179:2181-6. PubMed
  • Vira MA, Guzzo T, Heitjan DF, Tomaszewski JE, D'Amico A, Wein AJ, Malkowicz SB. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known? BJU Int 2008; 101:1232-6. PubMed
  • D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Tumor Volume Changes on 1.5 Tesla Endorectal MRI During Neoadjuvant Androgen Suppression Therapy for Higher-Risk Prostate Cancer and Recurrence in Men Treated Using Radiation Therapy Results of the Phase II CALGB 9682 Study. Int J Radiat Oncol Biol Phys 2007; 71:9-15. PubMed
  • D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology 2008; 71:933-7. PubMed
  • Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR. Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: From the CaPSUREtrade mark database. Urol Oncol 2008; 26:271-5. PubMed
  • Nguyen PL, D'Amico AV. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 2008; 26:2055-6; author reply 2056-7. PubMed
  • Albert M, Song JS, Schultz D, Cormack RA, Tempany CM, Haker S, Devlin PM, Beard C, Hurwitz MD, Suh WW, Jolesz F, D'Amico AV. Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate. Urol Oncol 2008; 26:147-52. PubMed
  • Sengupta S, Amling C, D'Amico AV, Blute ML. Prostate specific antigen kinetics in the management of prostate cancer. J Urol 2008; 179:821-6. PubMed
  • D'Amico AV. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer. J Clin Oncol 2008; 26:823-4. PubMed
  • D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299:289-95. PubMed
  • Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology 2008; 71:136-40. PubMed
  • D'Amico AV, Kantoff PW, Chen MH. Aspirin and hormone therapy for prostate cancer. N Engl J Med 2007; 357:2737-8. PubMed
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 2007; 110:2210-7. PubMed
  • Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer. Cancer 2007; 110:1973-8. PubMed
  • Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute 2007; 99:1516-24. PubMed
  • D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 2007; 110:1723-8. PubMed
  • Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 2007; 298:1533-8. PubMed
  • Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007; 110:1485-92. PubMed
  • Alexander BM, Chen MH, Carroll P, D'Amico AV. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response. Urology 2007; 70:320-3. PubMed
  • Nguyen PL, Chen MH, Renshaw AA, Sussman B, D'Amico AV. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology 2007; 70:288-93. PubMed
  • D'Amico AV, Denham JW, Bolla M, Collette L, Lamb DS, Tai KH, Steigler A, Chen MH. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 2007; 109:2004-10. PubMed
  • Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'amico A, Bernardini C, Mirabella M, Silvestri G, Giglio V, Modoni A, Pedemonte M, Tasca G, Galluzzi G, Mercuri E, Tonali PA, Ricci E. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J 2007; 21:1210-26. PubMed
  • D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer 2007; 109:1290-5. PubMed
  • Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer 2007; 109:1493-1498. PubMed
  • Krejcarek SC, Chen MH, Renshaw AA, Loffredo M, Sussman B, D'Amico AV. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer. Urology 2007; 69:515-9. PubMed
  • Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the re J Urol 2007; 177:540-5. PubMed
  • D'Amico AV. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. J Clin Oncol 2006; 25:8-9. PubMed
  • D'Amico A. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. BJU Int 2007; 99 Suppl 1:13-6; discussion 17-8. PubMed
  • Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006; 107:2597-603. PubMed
  • D'Amico AV, Hui-Chen M, Renshaw AA, Sussman B, Roehl KA, Catalona WJ. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006; 176:S11-5. PubMed
  • Chen AB, D'Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006; 24:5298-304. PubMed
  • Court LE, D'Amico AV, Kadam D, Cormack R. Motion and shape change when using an endorectal balloon during prostate radiation therapy. Radiother Oncol 2006; 81:184-9. PubMed
  • D'Amico AV, Barry MJ. Prostate cancer prevention and finasteride. J Urol 2006; 176:2010-2; discussion 2012-3. PubMed
  • Petit JH, Chen MH, Loffredo M, Sussman B, Renshaw AA, D'Amico AV. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer 2006; 107:2180-5. PubMed
  • Beard C, Schultz D, Loffredo M, Cote K, Renshaw AA, Hurwitz MD, D'Amico AV. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66:403-7. PubMed
  • Rosa GD, Deodato F, Loupatty FJ, Rizzo C, Carrozzo R, Santorelli FM, Boenzi S, D'Amico A, Tozzi G, Bertini E, Maiorana A, Wanders RJ, Dionisi-Vici C. Hypertrophic cardiomyopathy, cataract, developmental delay, lactic acidosis: A novel subtype of 3-methylglutaconic aciduria. J Inherit Metab Dis 2006; 29:546-50. PubMed
  • Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV. Radical prostatectomy for high-grade prostate cancer. Urology 2006; 68:367-70. PubMed
  • Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 2006; 107:514-20. PubMed
  • Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 2006; 68:342-7. PubMed
  • Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE,. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4:548-82. PubMed
  • D'Amico AV, Kantoff P, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 2006; 65:656-60. PubMed
  • Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res 2006; 12:3596s-600s. PubMed
  • Ajani J, Bekaii-Saab T, D'Amico TA, Fuchs C, Gibson MK, Goldberg M, Hayman JA, Ilson DH, Javle M, Kelley S, Kurtz RC, Locker GY, Meropol NJ, Minsky BD, Orringer MB, Osarogiagbon RU, Posey JA, Roth J, Sasson AR, Swisher SG, Wood DE, Yen Y. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2006; 4:350-66. PubMed
  • D'Amico AV, Manola J, McMahon E, Loffredo M, Lopes L, Ching J, Albert M, Hurwitz M, Suh WW, Vivenzio TA, Beard C. A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization. Urology 2006; 67:780-4. PubMed
  • Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level. Cancer 2006; 106:1507-13. PubMed
  • Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175:907-12. PubMed
  • Guzzo TJ, Vira M, Wang Y, Tomaszewski J, D'amico A, Wein AJ, Malkowicz SB. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol 2006; 175:518-21; discussion 521-2. PubMed
  • Jones GB, Crasto CF, Mathews JE, Xie L, Mitchell MO, El-Shafey A, D'Amico AV, Bubley GJ. An image contrast agent selectively activated by prostate specific antigen. Bioorg Med Chem 2005; 14:418-25. PubMed
  • Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 2005; 106:63-7. PubMed
  • Punglia RS, Kuntz KM, Catalona WJ, D'Amico A. Operating characteristics of prostate-specific antigen and verification bias. JAMA 2005; 294:2698; author reply 2698-9. PubMed
  • Barnes AS, Haker SJ, Mulkern RV, So M, D'Amico AV, Tempany CM. Magnetic resonance spectroscopy-guided transperineal prostate biopsy and brachytherapy for recurrent prostate cancer. Urology 2005; 66:1319. PubMed
  • Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 2005; 23:8192-7. PubMed
  • Kadoch C, D'Amico AV, Matthews RH. When prostate brachytherapy fails: a case report and discussion. Oncologist 2005; 10:799-805. PubMed
  • Vira MA, Tomaszewski JE, Hwang WT, D'Amico AV, Whittington R, Vanarsdalen K, Wein AJ, Malkowicz SB. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology 2005; 66:1015-9. PubMed
  • Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology 2005; 66:1024-8. PubMed
  • Beard C, Chen MH, Cote K, Loffredo M, Renshaw A, Hurwitz M, D'Amico AV. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer. Urology 2005; 66:1020-3. PubMed
  • Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005; 23:6992-8. PubMed
  • Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, Moul JW, D'Amico AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23:6556-60. PubMed
  • D'Amico AV, Chen MH, Cox MC, Dahut W, Figg WD. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology 2005; 66:571-6. PubMed
  • McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, Richie JP, D'Amico AV. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol 2005; 23:311-7. PubMed
  • Guzzo TJ, Vira M, Hwang WT, D'amico A, Tomaszewski J, Whittington R, Wein AJ, Vanarsdalen K, Malkowicz SB. Impact of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy. Urology 2005; 66:361-5. PubMed
  • D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005; 23:4975-9. PubMed
  • Tsai HK, Manola J, Abner A, Talcott JA, D'Amico AV, Beard C. Patient-reported acute gastrointestinal toxicity in men receiving 3-dimensional conformal radiation therapy for prostate cancer with or without neoadjuvant androgen suppression therapy. Urol Oncol 2005; 23:230-7. PubMed
  • Woel R, Beard C, Chen MH, Hurwitz M, Loffredo M, McMahon E, Ching J, Lopes L, D'Amico AV. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization. Int J Radiat Oncol Biol Phys 2005; 62:392-6. PubMed
  • Nguyen PL, Whittington R, Koo S, Schultz D, Cote KB, Loffredo M, McMahon E, Renshaw AA, Tomaszewski JE, D'Amico AV. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer 2005; 103:2053-9. PubMed
  • D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 173:1572-6. PubMed
  • Landis DM, Schultz D, Cormack R, Tempany C, Beard C, Hurwitz M, O'Leary M, Albert M, Valentine K, D'Amico AV. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology 2005; 65:750-4. PubMed
  • Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology 2005; 65:528-32. PubMed
  • Beard CJ. The risk of bladder, bowel, and sexual dysfunction after radiation therapy: what the data tell us and how we can use it to counsel our patients. Cancer J 2005; 11:106-9. PubMed
  • D'Amico AV. Screening for prostate carcinoma: prostate-specific antigen--friend or foe? Cancer 2005; 103:881-3. PubMed
  • Song JS, Albert M, D'Amico AV, Cormack RA. A comparative study of rectal dose histograms in prostate brachytherapy: some analytic and numerical results. Med Phys 2005; 32:437-47. PubMed
  • D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M, Chen MH. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 2004; 22:3726-32. PubMed
  • D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292:821-7. PubMed
  • Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004; 10:3927-33. PubMed
  • Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'amico AV. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004; 63:333-6. PubMed
  • Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M, D'Amico AV. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 2003; 58:19-24. PubMed
  • D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003; 170:S42-6; discussion S46-7. PubMed
  • D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003; 62:1063-7. PubMed
  • Talcott JA, Manola J, Clark JA, Kaplan I, Beard CJ, Mitchell SP, Chen RC, O'Leary MP, Kantoff PW, D'Amico AV. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 2003; 21:3979-86. PubMed
  • Sanghani MV, Schultz D, Tempany CM, Titelbaum D, Renshaw AA, Loffredo M, Cote K, McMahon B, D'Amico AV. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 2003; 62:487-91. PubMed
  • Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349:335-42. PubMed
  • D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21:2163-72. PubMed
  • D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169:1320-4. PubMed
  • D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma. Cancer 2002; 97:56-62. PubMed
  • D'Amico AV, Toupless G, Lopes L, Valentine KJ, Cormack RA, Tempany CM, Kumar S, Marks PJ. Self-administration of untested medical therapy for treatment of prostate cancer can lead to clinically significant adverse events. Int J Radiat Oncol Biol Phys 2002; 54:1311-3. PubMed
  • D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20:4567-73. PubMed
  • Das P, Chen MH, Valentine K, Lopes L, Cormack RA, Renshaw AA, Tempany CM, Kumar S, D'Amico AV. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 2002; 54:698-702. PubMed
  • D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002; 54:436-41. PubMed
  • Yoon JH, Chen MH, Renshaw AA, Richie JP, D'Amico AV. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer. Urology 2002; 60:454-7. PubMed
  • Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002; 60:458-63. PubMed
  • Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20:3199-205. PubMed
  • Hirose M, Bharatha A, Hata N, Zou KH, Warfield SK, Cormack RA, D'Amico A, Kikinis R, Jolesz FA, Tempany CM. Quantitative MR imaging assessment of prostate gland deformation before and during MR imaging-guided brachytherapy. Acad Radiol 2002; 9:906-12. PubMed
  • D'Amico AV. Predicting prostate-specific antigen recurrence established: now, who will survive? J Clin Oncol 2002; 20:3188-90. PubMed
  • Hurwitz MD, Schnieder L, Manola J, Beard CJ, Kaplan ID, D'Amico AV. Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys 2002; 53:1106-10. PubMed
  • Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M, Wein A, Richie JP, D'Amico AV. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53:898-903. PubMed
  • D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer 2002; 95:275-80. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95:281-6. PubMed
  • D'Amico AV, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrzytzky O, Renshaw AA. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53:581-7. PubMed
  • Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington R, Tomaszewski JE, Renshaw AA, Richie JP, D'Amico AV. Impact of race on prostate-specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol 2002; 20:2863-8. PubMed
  • Linson PW, Lee AK, Doytchinova T, Chen MH, Weinstein MH, Richie JP, D'Amico AV. Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer? Urology 2002; 59:704-8. PubMed
  • Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-9. PubMed
  • Bharatha A, Hirose M, Hata N, Warfield SK, Ferrant M, Zou KH, Suarez-Santana E, Ruiz-Alzola J, D'Amico A, Cormack RA, Kikinis R, Jolesz FA, Tempany CM. Evaluation of three-dimensional finite element-based deformable registration of pre- and intraoperative prostate imaging. Med Phys 2002; 28:2551-60. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, Rhude M, Rocha S, Wein A, Richie JP. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166:2185-8. PubMed
  • D'Amico AV, Manola J, Loffredo M, Lopes L, Nissen K, O'Farrell DA, Gordon L, Tempany CM, Cormack RA. A practical method to achieve prostate gland immobilization and target verification for daily treatment. Int J Radiat Oncol Biol Phys 2001; 51:1431-6. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Renshaw AA, Tomaszewski JE, Bentley C, Schultz D, Rocha S, Wein A, Richie JP. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology 2001; 58:406-10. PubMed
  • Hata N, Jinzaki M, Kacher D, Cormak R, Gering D, Nabavi A, Silverman SG, D'Amico AV, Kikinis R, Jolesz FA, Tempany CM. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology 2001; 220:263-8. PubMed
  • D'Amico AV, Cormack RA, Tempany CM. MRI-guided diagnosis and treatment of prostate cancer. N Engl J Med 2001; 344:776-7. PubMed
  • D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 49:679-84. PubMed
  • Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 2001; 49:673-7. PubMed
  • Cheung R, Altschuler MD, D'Amico AV, Malkowicz SB, Wein AJ, Whittington R. ROC optimization may improve risk stratification of prostate cancer patients. Urology 2001; 57:286-90. PubMed
  • D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2000; 165:126-9. PubMed
  • D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol 2000; 18:3240-6. PubMed
  • D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000; 284:1280-3. PubMed
  • Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ. Towards enzyme activated antiprostatic agents. Bioorg Med Chem Lett 2000; 10:1987-9. PubMed
  • D'Amico AV, Whittington R, Malkowicz B, Schnall M, Schultz D, Cote K, Tomaszewski JE, Wein A. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000; 164:759-63. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol 2000; 4:171-5;discussion 177. PubMed
  • D'Amico AV, Weinstein M, Li X, Richie JP, Fujimoto J. Optical coherence tomography as a method for identifying benign and malignant microscopic structures in the prostate gland. Urology 2000; 55:783-7. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55:572-7. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18:1164-72. PubMed
  • Kovtun KA, Wolfsberger L, Niedermayr T, Sugar EN, Graham PL, Murciano-Goroff Y, Beard C, D'Amico AV, Martin NE, Orio PF, Nguyen PL. Dosimetric quality and evolution of edema after low-dose-rate brachytherapy for small prostates: implications for the use of newer isotopes. Brachytherapy 2014; 13:152-6. PubMed
  • Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy 2014; 13:27-31. PubMed
  • Cheung AK, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin M, Ross R, D'Amico AV. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement. Brachytherapy 2010; 9:145-50. PubMed
  • Kooy HM, Cormack RA, Mathiowitz G, Tempany C, D'Amico AV. A software system for interventional magnetic resonance image-guided prostate brachytherapy. Comput Aided Surg 2001; 5:401-13. PubMed
  • D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis Assoc Disord 2010; 24:85-9. PubMed
  • Ficarra V, Righetti R, D'Amico A, Pilloni S, Balzarro M, Schiavone D, Malossini G, Mobilio G. General state of health and psychological well-being in patients after surgery for urological malignant neoplasms. Urol Int 2000; 65:130-4. PubMed
  • Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, Desantis C, Smith RA. American cancer society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60:70-98. PubMed
  • Nguyen PL,Chen RC,Clark JA,Cormack RA,Loffredo M,McMahon E,Nguyen AU,Suh WW,Tempany CM,D'Amico AV. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study. Brachytherapy 2009; 8:345-52. PubMed
  • Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, . Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010; 60:194-201. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys 1999; 45:1227-33. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17:168-72. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Tomaszewski JE, Wein A. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998; 160:2096-101. PubMed
  • D'Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, Loughlin KR, Richie JP. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer 1998; 83:2172-80. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 1998; 52:631-6. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969-74. PubMed
  • Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998; 83:748-52. PubMed
  • D'Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 1998; 82:1887-96. PubMed
  • D'Amico AV, Schnall M, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 1998; 51:449-54. PubMed
  • D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997; 158:1422-6. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. J Clin Oncol 1997; 15:1465-9. PubMed
  • D'Amico AV, Chang H, Holupka E, Renshaw A, Desjarden A, Chen M, Loughlin KR, Richie JP. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997; 49:385-91. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol 1996; 14:1770-7. PubMed
  • D'Amico AV, Propert KJ. Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 1996; 35:273-9. PubMed
  • D'Amico AV, Kaplan I. Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate-specific antigen levels. Radiother Oncol 1996; 38:73-6. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32:473-7. PubMed
  • D'Amico AV, Whittington R, Schnall M, Malkowicz SB, Tomaszewski JE, Schultz D, Wein A. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer 1995; 75:2368-72. PubMed
  • D'Amico AV, McKenna WG. Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiother Oncol 1994; 33:3-10. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, VanArsdalen K, Wein A. A multivariable analysis of clinical factors predicting for pathological features associated with local failure after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1994; 30:293-302. PubMed
  • D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993; 72:2638-43. PubMed
Hide